Last reviewed · How we verify
NCT07281300
Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer
NA trial testing Mindfulness-Oriented Respiratory Distress Symptom Intervention (M-RDSI) in Symptom Cluster in 64 participants. Currently enrolling.
30 June 2027
Quick facts
| Lead sponsor | The Hong Kong Polytechnic University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | supportive care |
| Enrollment | 64 |
| Start date | 12 August 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 30 July 2027 |
| Sites | 1 location across Hong Kong |
Drugs / interventions tested
- Mindfulness-Oriented Respiratory Distress Symptom Intervention (M-RDSI)
- Usual Care
Conditions studied
- Symptom Cluster — all drugs for Symptom Cluster →
- Breathlessness — all drugs for Breathlessness →
- Coughing — all drugs for Coughing →
- Fatigue Symptom — all drugs for Fatigue Symptom →
Sponsor
The Hong Kong Polytechnic University
Who can join
18 and older, any sex, with Symptom Cluster or Breathlessness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung cancer is the leading cause of cancer mortality, posing a critical public health challenge in both Hong Kong and global populations. Patients with lung cancer frequently experience a distressing symptom cluster characterized by breathlessness-driven respiratory distress, accompanied by persistent cough and fatigue, which collectively impose a substantial disease burden. While our research team leader previously developed and validated a multi-component Respiratory Distress Symptom Intervention (RDSI) in England, demonstrating clinical efficacy for lung cancer management, its impact on psychological distress (anxiety and depression) proved limited. This limitation may reflect insufficient integration of psychological components, a crucial consideration given the well-established bidirectional relationship between respiratory symptoms and psychological distress. Emerging evidence indicates that mindfulness interventions provide dual therapeutic benefits by improving patient adherence and effectively addressing both physical symptoms, such as breathlessness and fatigue, as well as psychological distress, including anxiety and depression. Meanwhile, current evaluation methodologies have mainly focused on behavioral data collection, such as self-reported questionnaires, to reflect the effect before and after the intervention. Neuroimaging data can help understand the brain mechanisms underlying breathlessness and elucidate the effectiveness of interventions, thereby improving intervention strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07281300
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Hong Kong Polytechnic University trials
Trials by the same sponsor.
- NCT07505732 — Information-providing Chatbot · NA · not yet recruiting
- NCT07391449 — Heart Rate Variability Guided Physical Activity and Exercise Prescription in Individuals With Knee Osteoarthritis · NA · not yet recruiting
- NCT07450248 — The Use of Telephone-based ACT for Quitting Alcohol in the Young Population With Hazardous or Harmful Alcohol Use. · NA · not yet recruiting
- NCT07273682 — Nurse-led Transitional Care to Improve Symptom Management in Childhood Cancer Survivors · NA · not yet recruiting
- NCT07459010 — ACT Dad's Power: Feasibility RCT for Fathers of Children With Special Needs · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07281300 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Hong Kong Polytechnic University
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07281300.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing